Bristol-Myers Squibb BMY Other Growth products — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's other growth products — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's other growth products — total revenues?
- Bristol-Myers Squibb (BMY) reported other growth products — total revenues of $653M in Q2 2026.
- How has Bristol-Myers Squibb's other growth products — total revenues changed year-over-year?
- Bristol-Myers Squibb's other growth products — total revenues increased by 38.9% year-over-year, from $470M to $653M.
- What is the long-term trend for Bristol-Myers Squibb's other growth products — total revenues?
- Over 3 years (2022 to 2025), Bristol-Myers Squibb's other growth products — total revenues has grown at a 20.8% compound annual growth rate (CAGR), from $1.09B to $1.92B.
- What does other growth products — total revenues mean?
- This metric represents the aggregate revenue generated from a specific portfolio of pharmaceutical products identified by the company as key growth drivers outside of its primary blockbuster franchises. These products typically include newer drug launches or specialized therapies that are in the early-to-mid stages of their commercial lifecycle. Monitoring this segment provides insight into the company's ability to diversify its revenue base and successfully commercialize its pipeline beyond legacy assets.